CEFAZOLIN SODIUM

Post-LOE

cefazolin

Novartis

ANDAINJECTIONINJECTABLE1 Generic Approved

Approved

May 2007

Lifecycle

Post-LOE

Competitive Pressure

45/100

Clinical Trials

Data completeness

2/8 — Basic

Drug data last refreshed 20h ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (8)

NCT05205486Phase 1Completed

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults

Started Apr 2022

12 enrolled

Infections

NCT05309304Phase 1Completed

Cefazolin PK Study 3g vs 2g

Started Feb 2022

24 enrolled

Healthy

NCT03231228Phase 4Terminated

Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects

Started Nov 2017

61 enrolled

Postoperative Infection

NCT01886742Phase 4Withdrawn

Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients

Started Sep 2017

Obesity

NCT00850122Phase 1Completed

An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates

Started Jul 2013

9 enrolled

SepsisPrematurity

Worked on CEFAZOLIN SODIUM at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.